SUTRO BIOPHARMA, INC. Research and Development Expense
SUTRO BIOPHARMA, INC. (STRO) reported Research and Development Expense of $31.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. research and development expense for the quarter ending 2026-06-30 was $31.70M, a 17.30% decline year-over-year.
- SUTRO BIOPHARMA, INC. research and development expense for the quarter ending 2026-03-31 was $36.55M, a 29.16% decline year-over-year.
- SUTRO BIOPHARMA, INC. research and development expense for the quarter ending 2025-12-31 was $36.64M, a 48.42% decline year-over-year.
- SUTRO BIOPHARMA, INC. research and development expense for the quarter ending 2025-09-30 was $39.85M, a 35.83% decline year-over-year.
- SUTRO BIOPHARMA, INC. research and development expense for fiscal 2025 was $166.42M, a 33.97% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. research and development expense for fiscal 2024 was $252.04M, a 39.69% increase from fiscal 2023.
- SUTRO BIOPHARMA, INC. research and development expense for fiscal 2023 was $180.43M, a 31.53% increase from fiscal 2022.
- SUTRO BIOPHARMA, INC. research and development expense for fiscal 2022 was $137.17M, a 31.39% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $31.70M 10-Q · filed 2026-08-12 | $68.25M 10-Q · filed 2026-08-12 | $104.89M derived: sum of 3 quarters · filed 2026-08-12 | $144.74M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $36.55M 10-Q · filed 2026-05-14 | $73.19M derived: sum of 2 quarters · filed 2026-05-14 | $113.05M derived: sum of 3 quarters · filed 2026-05-14 | $151.37M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $36.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $76.50M derived: sum of 2 quarters · filed 2026-03-23 | $114.82M derived: sum of 3 quarters · filed 2026-08-12 | $166.42M 10-K · filed 2026-03-23 |
| 2025-09-30 | $39.85M 10-Q · filed 2025-11-06 | $78.18M derived: sum of 2 quarters · filed 2026-08-12 | $129.78M 10-Q · filed 2025-11-06 | $200.81M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $38.33M 10-Q · filed 2026-08-12 | $89.92M 10-Q · filed 2026-08-12 | $160.96M derived: sum of 3 quarters · filed 2026-08-12 | $223.07M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $51.60M 10-Q · filed 2026-05-14 | $122.63M derived: sum of 2 quarters · filed 2026-05-14 | $184.74M derived: sum of 3 quarters · filed 2026-05-14 | $246.76M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $71.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $133.15M derived: sum of 2 quarters · filed 2026-03-23 | $195.16M derived: sum of 3 quarters · filed 2026-03-23 | $252.04M 10-K · filed 2026-03-23 |
| 2024-09-30 | $62.11M 10-Q · filed 2025-11-06 | $124.13M derived: sum of 2 quarters · filed 2025-11-06 | $181.01M 10-Q · filed 2025-11-06 | $234.77M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $62.02M 10-Q · filed 2025-08-07 | $118.90M 10-Q · filed 2025-08-07 | $172.66M derived: sum of 3 quarters · filed 2025-08-07 | $218.33M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $56.88M 10-Q · filed 2025-05-08 | $110.64M derived: sum of 2 quarters · filed 2025-05-08 | $156.31M derived: sum of 3 quarters · filed 2025-05-08 | $197.90M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $53.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $99.43M derived: sum of 2 quarters · filed 2025-03-13 | $141.03M derived: sum of 3 quarters · filed 2025-03-13 | $180.43M 10-K · filed 2025-03-13 |
| 2023-09-30 | $45.67M 10-Q · filed 2024-11-13 | $87.26M derived: sum of 2 quarters · filed 2024-11-13 | $126.66M 10-Q · filed 2024-11-13 | $169.79M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $41.59M 10-Q · filed 2024-08-13 | $80.99M 10-Q · filed 2024-08-13 | $124.13M derived: sum of 3 quarters · filed 2025-03-13 | $155.84M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $39.40M 10-Q · filed 2024-05-13 | $82.53M derived: sum of 2 quarters · filed 2025-03-13 | $114.25M derived: sum of 3 quarters · filed 2025-03-13 | $146.58M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $43.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $74.85M derived: sum of 2 quarters · filed 2025-03-13 | $107.18M derived: sum of 3 quarters · filed 2025-03-13 | $137.17M 10-K · filed 2025-03-13 |
| 2022-09-30 | $31.71M 10-Q · filed 2023-11-13 | $64.05M derived: sum of 2 quarters · filed 2023-11-13 | $94.04M 10-Q · filed 2023-11-13 | $123.96M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | $32.33M 10-Q · filed 2023-08-10 | $62.32M 10-Q · filed 2023-08-10 | $92.25M derived: sum of 3 quarters · filed 2024-03-25 | $118.85M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | $29.99M 10-Q · filed 2023-05-15 | $59.92M derived: sum of 2 quarters · filed 2024-03-25 | $86.52M derived: sum of 3 quarters · filed 2024-03-25 | $111.83M derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | $29.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $56.53M derived: sum of 2 quarters · filed 2024-03-25 | $81.84M derived: sum of 3 quarters · filed 2024-03-25 | $104.40M 10-K · filed 2024-03-25 |
| 2021-09-30 | $26.60M 10-Q · filed 2022-11-08 | $51.91M derived: sum of 2 quarters · filed 2022-11-08 | $74.47M 10-Q · filed 2022-11-08 | $97.21M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-06-30 | $25.31M 10-Q · filed 2022-08-08 | $47.87M 10-Q · filed 2022-08-08 | $70.61M derived: sum of 3 quarters · filed 2023-03-30 | $89.97M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-03-31 | $22.56M 10-Q · filed 2022-05-09 | $45.30M derived: sum of 2 quarters · filed 2023-03-30 | $64.66M derived: sum of 3 quarters · filed 2023-03-30 | $81.90M derived: sum of 4 quarters · filed 2023-03-30 |
| 2020-12-31 | $22.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $42.10M derived: sum of 2 quarters · filed 2023-03-30 | $59.34M derived: sum of 3 quarters · filed 2023-03-30 | $76.96M 10-K · filed 2023-03-30 |
| 2020-09-30 | $19.36M 10-Q · filed 2021-11-10 | $36.60M derived: sum of 2 quarters · filed 2021-11-10 | $54.22M 10-Q · filed 2021-11-10 | $71.61M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $17.24M 10-Q · filed 2021-08-09 | $34.86M 10-Q · filed 2021-08-09 | $52.25M derived: sum of 3 quarters · filed 2022-02-28 | $69.15M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $17.62M 10-Q · filed 2021-05-07 | $35.01M derived: sum of 2 quarters · filed 2022-02-28 | $51.91M derived: sum of 3 quarters · filed 2022-02-28 | $68.05M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $17.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $34.29M derived: sum of 2 quarters · filed 2022-02-28 | $50.43M derived: sum of 3 quarters · filed 2022-02-28 | $65.61M 10-K · filed 2022-02-28 |
| 2019-09-30 | $16.90M 10-Q · filed 2020-11-05 | $33.04M derived: sum of 2 quarters · filed 2020-11-05 | $48.22M 10-Q · filed 2020-11-05 | $63.01M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | $16.14M 10-Q · filed 2020-08-06 | $31.32M 10-Q · filed 2020-08-06 | $46.11M derived: sum of 3 quarters · filed 2021-03-18 | $58.75M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | $15.18M 10-Q · filed 2020-05-11 | $29.97M derived: sum of 2 quarters · filed 2021-03-18 | $42.61M derived: sum of 3 quarters · filed 2021-03-18 | $56.36M derived: sum of 4 quarters · filed 2021-03-18 |
| 2018-12-31 | $14.79M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $27.43M derived: sum of 2 quarters · filed 2021-03-18 | $41.18M derived: sum of 3 quarters · filed 2021-03-18 | $54.26M 10-K · filed 2021-03-18 |
| 2018-09-30 | $12.64M 10-Q · filed 2019-11-08 | $26.39M derived: sum of 2 quarters · filed 2019-11-08 | $39.48M 10-Q · filed 2019-11-08 | $54.62M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $13.75M 10-Q · filed 2019-08-14 | $26.83M 10-Q · filed 2019-08-14 | $41.97M derived: sum of 3 quarters · filed 2020-03-16 | $55.64M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-03-31 | $13.08M 10-Q · filed 2019-05-15 | $28.22M derived: sum of 2 quarters · filed 2020-03-16 | $41.89M derived: sum of 3 quarters · filed 2020-03-16 | |
| 2017-12-31 | $15.14M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $28.81M derived: sum of 2 quarters · filed 2020-03-16 | $54.64M 10-K · filed 2020-03-16 | |
| 2017-09-30 | $13.67M 10-Q · filed 2018-11-14 | $39.50M 10-Q · filed 2018-11-14 | ||
| 2016-12-31 | $43.55M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |